NCT01976650 - Safety and Efficacy of Dexamethasone (OZURDEX®) Intravitreal Implant in Korea | Biotech Hunter

Enrollment

724

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions

Retinal Vein Occlusion

Interventions

DRUG

dexamethasone 700 ㎍ intravitreal implant

dexamethasone 700 ㎍ (OZURDEX®) intravitreal implant treatment for Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, or non-infectious uveitis affecting the posterior segment of the eye as per local standard of care in clinical practice.

Trial Locations (1)

Unknown

Seoul